IRLAB is a Swedish biotech company listed on the Nasdaq Stockholm Main Market. The company is focused on the discovery and development of novel drugs for neurological diseases, with a primary focus on Parkinson’s disease. IRLAB is currently in mid-stage clinical trials for its two lead drug candidates: mesdopetam (for levodopa-induced dyskinesia in Parkinson’s disease, which has been out-licensed to Ipsen), and pirepemat (for reducing falls in Parkinson’s disease). IRLAB’s clinical and pre-clinical candidate drugs all stem from its proprietary drug discovery platform, ISP.
Clinical development failure is IRLAB’s greatest risk. The clinical success of competing compounds could also pose a risk, by lowering the unmet medical need or changing the current standard of care. Commercial risks include a failure to demonstrate sufficiently relevant clinical improvements, and/or a failure to out-license its drug candidates to potential partners.